Platelet transfusion: Products, indications, dose, threshold and efficacy;Transfusion de plaquettes : produits, indications, dose, seuil, efficacité

Transfusion Clinique et Biologique

Volumn 16, Issue 2, 2009, Pages 118-133

  Andreu, G ^a   Vasse, J ^b   Tardivel, R ^b   Semana, G ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b ETS de Bretagne   (France)

Author keywords

Allo immunization; Platelet; Platelet components; Platelet transfusion; Thrombocytopenia

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE;

ALLOIMMUNITY; ALLOIMMUNIZATION; APHERESIS; AUTHORITY; BLEEDING; BLOOD COMPATIBILITY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PRACTICE; CRYOPRESERVATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISSEMINATED INTRAVASCULAR CLOTTING; DONOR; HLA SYSTEM; HUMAN; IRRADIATION; OBSTETRICS; PATHOGENESIS; PHENOTYPE; PRACTICE GUIDELINE; QUALITY CONTROL; SAFETY; SHORT SURVEY; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; VEIN OCCLUSION; CELL SEPARATION; DISEASE TRANSMISSION; REVIEW;

CELL SEPARATION; DISEASE TRANSMISSION, INFECTIOUS; HEMORRHAGE; HUMANS; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 66049159730     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2009.04.001     Document Type: Short Survey

References (105)

1. Duke W. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 14 (1910) 1185
2. Gaydos L.A., Freireich E.J., and Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266 (1962) 905-909
3. Mourad N. A simple method for obtaining platelet concentrates free of aggregates. Transfusion 1 (1968) 48
4. Pietersz R.N.I., Loos J.A., and Reesink H.W. Platelet concentrates stored in plasma for 72 hours at 22 °C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. Vox Sang 49 (1985) 81-85
5. Cid J., Ramiro L., Escoda L., and Llorente A. Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval. Vox Sang 96 (2009) 29-33
6. Tardivel R., Bois S., Massot D., and Semana G. Orbisac : un automate permettant d'améliorer et de standardiser la production des MCP. Transfus Clin Biol 14 (2007) 213
7. Chabanel A., Masse M., and Bégué S. National French observatory of the quality of blood components for transfusion. Transfus Clin Biol 15 (2008) 85-90
8. Nollet K.E., and Holland P.V. Toward a coalition against transfusion-associated GVHD. Transfusion 43 (2003) 1655-1657
9. Rock G., Adams G.A., and Labow R.S. The effects of irradiation on platelet function. Transfusion 28 (1988) 451-455
10. Ford J.M., Cullen M.H., Lucey J.J., Tobias J.S., and Lister T.A. Fatal graft-versus host disease following transfusion of granulocytes from normal donors. Lancet 2 (1976) 1167-1169
11. Parkman R., Mosier D., Umansky I., Cochran W., Carpenter C.B., and Rosen F.S. Graft-versus-host disease after intrauterine and exchange transfusions for hemolytic disease of the newborn. N Engl J Med 290 (1974) 359-363
12. Park B.H., Good R.A., Gate J., and Burke B. Fatal graft-vs-host reaction following transfusion of allogeneic blood and plasma in infants with combined immunodeficiency disease. Transplant Proc 6 (1974) 385-387
13. Thomas E.D., Herman Jr. E.C., Greenough III W.B., Hager E.B., Cannon J.H., Sahler O.D., et al. Irradiation and marrow infusion in leukemia. Observations in five patients with acute leukemia treated by whole-body exposures of 1400 to 2000 roentgens and infusions of marrow. Arch Intern Med 107 (1961) 829-845
14. Thaler M., Shamiss A., Orgad S., Huszar M., Nussinovitch N., Meisel S., et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 321 (1989) 25-28
15. Otsuka S., Kunieda K., Kitamura F., Misawa K., Jasaoka I., Hirose M., et al. The critical role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease in immunocompetent patients. Transfusion 31 (1991) 260-264
16. Baglin T.P., Joysey V.C., Horsford J., Johnson R.T., Broadbent V., and Marcus R.E. Transfusion associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma. Transfus Med 2 (1992) 195-199
17. Appleton A.L., Sviland L., Pearson A.D., Wilkes J., Green M.A., and Malcolm A.J. Diagnostic features of transfusion associated graft versus host disease. J Clin Pathol 47 (1994) 541-546
18. Leitman S.F., Tisdale J.F., Bolan C.D., Popovsky M.A., Klippel J.H., Balow J.E., et al. Transfusion associated GvHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 43 (2003) 1667-1671
19. Klein C., Fraitag S., Foulon E., Raffoux C., Bodemer C., and Blanche S. Moderate and transient transfusion-associated cutaneous graft-versus-host disease in a child infected by human immunodeficiency virus. Am J Med 101 (1996) 445-446
20. Stainsby D., Jones H., Asher D., Atterbury C., Boncinelli A., Brant L., et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 20 (2006) 273-282
21. Transfusion, de plaquettes: produits, indication, juin 2003 http://www.afssaps.fr/Afssaps-media/Publications/Recommandations-de-bonne-pratique (site consulté le 5 mai 2009).
22. Murphy M.F., and Bussel J.B. Advances in the management of alloimmune thrombocytopenia. Br J Haematology 136 (2007) 366-378
23. Pineda A.A., Zylstra V.W., Clare D.E., Dewanjee M.K., and Forstrom L.A. Viability and functional integrity of washed platelets. Transfusion 29 (1989) 524-527
24. Josephson C.D., Su L.L., Christensen R.D., Hillyer C.D., Castillejo M.I., Emory M.R., et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 123 (2009) 278-285
25. Dumont L.J., Kriladsiri P., Seghatchian J., Taylor L.A., Howell C.A., and Murphy M.F. Preparation and storage characteristics of white cell-reduced high concentration platelet concentrates collected by an apheresis system for transfusion in utero. Transfusion 40 (2000) 91-100
26. Schoenfeld H., Spies C., and Jakob C. Volume-reduced platelet concentrates. Curr Hematol Rep 5 (2006) 82-88
27. Dijkstra-Tiekstra M.J., de Korte D., Pietersz R.N.I., Reesink H.W., van der Meer P.F., and Verhoeven A.J. Comparison of various dimethylsulphoxide-containing solutions for cryopreservation of leucoreduced platelet concentrates. Vox Sang 4 (1985) 276-282
28. Van der Meer P.F., Vrielink H., and Pietersz R.N. Preparation and storage of white blood cell-reduced split apheresis platelet concentrates for pediatric use. Transfusion 45 (2005) 223-227
29. Andreu G., Vasse J., Herve F., Tardivel R., and Semana G. Introduction des solutions de conservation de plaquettes. Avantages, dévantages et benefices pour les patients. Transfus Clin Biol 14 (2007) 100-106
30. Rebibo D., Simonet M., and Hauser L. Introduction des solutions additives dans les concentres de plaquettes: vers une diminution des reactions transfusionnelles. Transfus Clin Biol 15 (2008) 289-293
31. Zhang J.G., Carter C.J., Culibrk B., Devine D.V., Levin E., Scammell K., et al. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma. Transfusion 48 (2008) 847-856
32. Azuma H., Hirayama J., Akino M., Miura R., Kiyama Y., Imai K., et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 49 (2009) 214-218
33. Lin L., Cook D.N., Wiesehahn G.P., Alfonso R., Behrman B., Cimino G.D., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
34. Van Rhenen D.J., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101 (2003) 2426-2433
35. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 104 (2004) 1534-1541
36. Roback J.D., Conlan M., Drew W.L., Ljungman P., Nichols W.G., and Preiksaitis J.K. The role of photochemical treatment with amotosalen and UVA light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 20 (2006) 45-56
37. Grellier P., Benach J., Labaied M., Charneau S., Gil H., Monsalve G., et al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of plasmodium and babesia in platelet and plasma components. Transfusion 48 (2008) 1676-1684
38. Van Voorhis W.C., Barrett L.K., Eastman R.T., Alfonso R., and Dupuis K. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother 47 (2003) 475-479
39. Grass J.A., Wafa T., Reames A., Wages D., Corash L., Ferrara J.L., et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 93 (1999) 3140-3147
40. Schlenke P. Protection against transfusion-associated graft-versus-host disease in blood transfusion: is gamma-irradiation the only answer?. Transfus Med Hemother 31 Suppl. 1 (2004) 24-31
41. Corash L., and Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 33 (2004) 1-7
42. Brooks E.G., MacPherson B.R., and Fung M.K. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 48 (2008) 2159-2166
43. James L., Gajewski, Viviana V., Johnson S., Gerald Sandler, Antoine Sayegh, et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 112 (2008) 3036-3047
44. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
45. Harker L.A., and Slichter S.J. The bleeding time as a screening test for evaluating platelet function. N Engl J Med 287 (1972) 155-159
46. Slichter S.J., and Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 7 (1978) 523-539
47. Hanson S.R., and Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 56 (1985) 1105-1109
48. Dutcher J.P., Schiffer C.A., Aisner J., O'Connell B.A., Levy C., Kendall J.A., et al. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 53 (1984) 557-562
49. Friedman A.M., Sengul H., Lehmann H., and SchwartzC GoodmanS. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A re-evaluation of prophylactic platelet transfusions. Transfus Med Rev 16 (2002) 34-45
50. Lawrence J.B., Yomtovian R.A., Dillman C., Masarik S.R., Chongkolwatana V., Creger R.J., et al. Reliability of automated platelet counts: comparison with manual method and utility for prediction of clinical bleeding. Am J Hematol 48 (1995) 244-250
51. Wandt H., Schaefer-Eckart K., Frank M., Birkmann J., and Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (2006) 387-392
52. Wandt H, Wendelin K, Schaefer-Eckart K, Thalheimer M, Scubert MS, Conradi R, et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood 2008;112, 11:112 [ASH abstract No. 286].
53. Harker L.A. The role of the spleen in thrombokinetics. J Lab Clin Med 77 (1971) 247-253
54. Slichter S.J., Davis K., Enright H., Braine H., Gernsheimer T., Kao K.J., et al. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105 (2005) 4106-4114
55. O'Connell B., Lee E.S., and Schiffer C.A. The value of 10-minute post-transfusion platelet counts. Transfusion 22 (1988) 66-67
56. Sensebé L., Giraudeau B., Bardiaux L., Deconinck E., Schmidt A., Bidet M.L., et al. The efficacy of high dose transfusions of platelets in hematologic thrombocytopenic patients: result of a prospective, randomized, open, blinded end point (PROBE) study. Blood 105 (2005) 862-864
57. Schiffer C.A., Lee E.J., Ness P.M., and Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood 67 (1986) 1591-1594
58. The Trial to Reduce Alloimmunization to Platelets Study Group. Leucocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-69.
59. Bock M., Muggenthaler K.H., Schmidt U., and Heim M.U. Influence of antibiotics on post-transfusion platelet increment. Transfusion 36 (1996) 952-954
60. Balduini C.L., Salvaneschi L., Klersy C., Noris P., Mazzucco M., Rizzuto F., et al. Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia 15 (2001) 1885-1891
61. Hussein M.A., Fletcher R., Long T.J., Zuccaro K., Bolwell B.J., and Hoeltge A. Transfusing platelets 2 h after the completion of amphotericin-B decreases its detrimental effect on transfused platelet recovery and survival. Transfus Med 8 (1998) 43-47
62. Rickles F.R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16 (2003) 463-482
63. Rio B., Andreu G., Nicod A., Arrago J.P., Dutrillaux F., Samama M., et al. Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy. Blood 67 (1986) 1773-1776
64. Maegele M, Lefering R, Paffrath T, Tjardes T, Simanski C, Bouillon B, et al. Red blood cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiply injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie. Vox Sang 2008;95:112-9.
65. Gonzalez E.A., Moore F.A., Holcomb J.B., Miller C.C., Kozar R.A., Todd S.R., et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 62 (2007) 112-119
66. Borgman M., Spinella P.C., Perkins J.G., Grathwohl K.W., Repine T., Beekley A.C., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63 (2007) 805-813
67. Dann E.J., Michaelson M., Barzelay M., Hoffmann R., and Bonstein L. Transfusion medicine during the summer of 2006: lessons learned in northern Israel. Transfus Med Rev 22 (2008) 70-76
68. Stinger H.K., Spinella P.C., Perkins J.G., Grathwohl K.W., Salinas J., Martini W.Z., et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 64 (2008) S79-85
69. Ho A.M., Karmakar M.K., and Dion P.W. Are we giving enough coagulation factors during major trauma resuscitation?. Am J Surg 190 (2005) 479-484
70. Holcomb J.B., Wade C.E., Michalek J.E., Chisholm G.B., Zarzabal L.A., Schreiber M.A., et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 248 (2008) 447-458
71. Johansson P.I., Stensballe J., Rosenberg I., Hilsløv T.L., Jørgensen L., and Secher N.H. Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 47 (2007) 593-598
72. Aderka D., Praff G., Santo M., Weinberger A., and Pinkhas J. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylatic platelet transfusion policy. Am J Med Sci 291 (1986) 147-151
73. Gmür J., Burger J., Schanz U., Fehr J., and Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 328 (1991) 1223-1226
74. Zumberg M.S., del Rosario M.L., Nejame C.F., Pollock B.H., Garzarella L., Kao K.J., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/microlitre versus 20,000/microlitre trigger. Biol Blood Marrow Transplant 8 (2002) 569-576
75. Rebulla P., Finazzi G., Marangoni F., Avvisati G., Gugliotta L., Tognoni G., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 337 (1997) 1870-1875
76. 9/l: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91 (1998) 3601-3606
77. Heckman K.D., Weiner G.J., Davis C.S., Strauss R.G., Jones M.P., and Burns C.P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microlitre versus 20,000/microlitre. J Clin Oncol 15 (1997) 1143-1149
78. 9 per L. Transfusion 47 (2007) 1700-1709
79. Kerkhoffs J.L.H., Eikenboom J.C.J., van deWatering L.M.G., vanWordragen-Vlaswinkel R.J., Wijermans P.W., and Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 48 (2008) 1959-1965
80. Norol F., Bierling P., Roudot-Thoraval F., Le Cœur F.F., Rieux C., Lavaux A., et al. Platelet transfusion: a dose-response study. Blood 92 (1998) 1448-1453
81. Klumpp T.R., Herman J.H., Gaughan J.P., Russo R.R., Christman R.A., Goldberg S.L., et al. Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 39 (1999) 674-681
82. Tinmouth A., Tannock I.F., Crump M., Tomlinson G., Brandwein J., Minden M., et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 44 (2004) 1711-1719
83. Slichter SJ, Kaufman RM, Assmann SF, Brecher ME, Gernsheimer T, Hillyer CD, et al. Effects of prophylactic platelet dose on transfusion outcomes (PLADO trial), Blood ASH annual meeting 2009, [abstract 285:111-2].
84. Aster R.H. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 26 (1965) 732-743
85. Cooling L. ABO and platelet transfusion therapy. Immunohematol 23 (2007) 20-33
86. Lapierre V., Mahé C., Aupérin A., Stambouli F., Oubouzar N., Tramalloni D., et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 80 (2005) 314-319
87. Benjamin R.J., McGurk S., Ralston M.S., Churchill W.H., and Antin J.H. ABO incompatibility as an adverse risk actor for survival after allogeneic bone marrow transplantation. Transfusion 39 (1999) 179-187
88. Fung M.K., Downes K.A., and Shulman I.A. Transfusion of platelets containing ABO-incompatible plasma. A survey of 3156 North American laboratories. Arch Pathol Lab Med 131 (2007) 909-916
89. Carr C., Hutton J.L., Jenkins J.A., Lucas G.F., and Amphlett N.W. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 75 (1990) 408-413
90. Heal J.M., Rowe J.M., McMican A., Masel D., Finke C., and Blumberg N. The role of ABO matching in platelet transfusion. Eur J Haematol 50 (1993) 110-117
91. Julmy F., Ammann R.A., Taleghani B.M., Fontana S., Hirt A., and Leibundgut K. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 49 (2009) 21-33
92. Heim D., Passweg J., Gregor M., Buser A., Theocharides A., Arber C., et al. Patient and product factors affecting platelet transfusion results. Transfusion 48 (2008) 681-687
93. Shanwell A, Andersson TM-L, Rostgaard K, Edgren G, Hjalgrim H, Norda R, et al. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma, Transfusion 2009. (Epub).
94. Blumberg N., Heal J.M., Hicks G.L., and Risher W.H. Association of ABO mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41 (2001) 790-793
95. Andreu G., Vasse J., Sandid I., Tardivel R., and Semana G. Use of random versus apheresis platelet concentrates. Transfus Clin Biol 14 (2007) 514-521
96. Afssaps, rapport d'activité hémovigilance 2006 : http://www.afssaps.fr/var/afssaps_site/storage/original/application/33f3e08a8705fb6ae47642045d2cadd5.pdf (site consulté le 5 mai 2009).
97. Willaert B., Vo Mai M.P., and Caldani C. French haemovigilance data on platelet transfusion. Transfus Med Hemother 35 (2008) 118-121
98. Alter H.J. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 22 (2008) 97-102
99. Klein H.G., Anderson D., Bernardi M.-J., Cable R., Carey W., Hoch J.S., et al. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference. Vox Sang 93 (2007) 179-182
100. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: pathogen inactivation. Making decisions about new technologies. Transfus Med Rev 22 (2008) 1-34
101. Rasonglès P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Reunion Island, Transfusion 2009. doi:10.1111/j.1537-2995.2009.02111.x. (Epub).
102. Osselaer J.C., Cazenave J.P., Lambermont M., Garraud O., Hidajat M., Barbolla L., et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 94 (2008) 315-323
103. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78 (2000) 211-215
104. Tolksdorf F., Walker W.H., Mohr H., Gravemann U., and Müller T.H. Pathogen reduction in platelet concentrates using uvc light in combination with strong agitation: effect on activation markers and storage stability. Transfusion 47 suppl. 131A (2007)
105. Andreu G., Caldani C., and Morel P. Reduction of septic transfusion reactions related to bacteria contamination without implementing bacteria detection. ISBT Science Series (2008) 3